Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Phathom Pharmaceuticals Inc.
Headquarters: Florham Park, NJ, United States of America
Website: https://www.phathompharma.com...
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Steven L. Basta, MBA
Number Of Employees: 427
Enterprise Value: $770,675,825
PE Ratio: -0.83
Exchange/Ticker 1: NASDAQ:PHAT
Exchange/Ticker 2: N/A
Latest Market Cap: $308,491,904
BioCentury | Apr 2, 2025
Management Tracks
Change at the top for Phathom as Basta replaces Curran
Plus: Updates from Nuage, GV, Inhibrx, Lyell, Repare, Adcendo, ITM Isotope, Transgene and Novartis
BioCentury | Aug 24, 2024
Finance
Public Equity Report: Signs of life for biotech IPOs as Zenas, Bicara file, TYK sticks landing
Pair of well-funded late-stage biotechs seek NASDAQ listings, Shanghai cancer company prices deal in Hong Kong
BioCentury | Aug 13, 2024
Data Byte
Summer lull as FDA approves only 2 NMEs in July
Total for the year stands at 26, lagging last year
BioCentury | Jul 3, 2024
Data Byte
Five PDUFA dates on deck for July
Decisions from FDA due on a nasal naloxone and Sprycel competitor, among others
BioCentury | Nov 1, 2023
Deals
Nov. 1 Quick Takes: AZ takes stake in Cellectis, eyes 25 targets in deal
Plus: RTW acquiring Arix Bioscience, and updates from Aldeyra, AbbVie, Silence, Lilly, Sitryx and more
BioCentury | Oct 31, 2023
Data Byte
Nine PDUFA dates on FDA’s November roster
Decisions include the first vaccine for Chikungunya and three new cancer therapies
BioCentury | Jun 13, 2023
Deals
June 12 Quick Takes: AZ’s first-in-class AKT inhibitor under review
Plus: Simcere grows Massachusetts presence, and updates from Eisai, Bliss, Eccogene, Phathom, Ironwood and more
BioCentury | May 25, 2023
Deals
May 24 Quick Takes: ElevateBio unveils $401M round, base editing deal with Novo
Plus: Phase III miss for Mirati’s sitravatinib in NSCLC and updates from CMS, Phathom, OnKure, Braeburn, Pyxis-Apexigen, IPI
BioCentury | Feb 11, 2023
Product Development
Feb. 10 Quick Takes: Aristea dissolving after safety findings
Plus: Abecma more than triples PFS in triple-class MM, and updates from Genentech, Phathom, Blueprint and more
BioCentury | Jan 11, 2023
Deals
Jan. 10 Quick Takes: AbbVie taps Anima for mRNA therapeutics
Plus updates from Alto, Union, AskBio-Recode, Phathom and more
Items per page:
1 - 10 of 35